Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 18/20 | 1.00 |
| ▸ | PPARA | Q07869 | 2/20 | 1.00 |
| ▸ | RXRA | P19793 | 2/20 | 0.56 |
| ▸ | RARG | P13631 | 1/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.50 |
| ▸ | MPC2 | O95563 | 1/20 | 0.49 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lobeglitazone SCHEMBL29356140 | 1.00 | PPARG (1.00) | PPARGPPARARXRARARGFFAR1 | |
| Lobeglitazone SCHEMBL20125580 | 1.00 | PPARG (1.00) | PPARGPPARARXRARARGFFAR1 | |
| Lobeglitazone SCHEMBL2742697 | 1.00 | PPARG (1.00) | PPARGPPARARXRARARGFFAR1 | |
| Lobeglitazone SCHEMBL29778221 | 0.97 | PPARG (1.00) | PPARGPPARARXRARARGFFAR1 | |
| SCHEMBL5884045 | 0.93 | PPARG (0.86) | PPARGPPARARXRARARGFFAR1 | |
| SCHEMBL19454945 | 0.92 | PPARG (0.85) | PPARGPPARARXRARARGFFAR1 | |
| SCHEMBL5883617 | 0.86 | PPARG (0.75) | PPARGPPARARXRARARGFFAR1 | |
| SCHEMBL5884168 | 0.85 | PPARG (0.74) | PPARGPPARARXRARARGFFAR1 | |
| SCHEMBL5883649 | 0.84 | PPARG (0.73) | PPARGPPARARXRARARGFFAR1 | |
| SCHEMBL5883494 | 0.82 | PPARG (0.69) | PPARGPPARARXRARARGFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200253937-A1 | 5-DEUTERO-THIAZOLIDINE-2,4-DIONE COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME | POXEL SA (FR) | 2020-08-13 | — | — | US | disclosed |
| US-20180125827-A1 | 5-DEUTERO-THIAZOLIDINE-2,4-DIONE COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME | DEUTERX, LLC | 2018-05-10 | — | — | US | disclosed |
| US-20180125827-A1 | 5-DEUTERO-THIAZOLIDINE-2,4-DIONE COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME | DEUTERX, LLC | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180125827-A1 | 5-DEUTERO-THIAZOLIDINE-2,4-DIONE COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME | DPP4, SLC5A2, GLP1R | PPARG 12/4885PPARA 26/4885RXRA 241/4885 |
| US-20200253937-A1 | 5-DEUTERO-THIAZOLIDINE-2,4-DIONE COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME | SLC5A2, GLI2, SLC5A1 | PPARG 13/4885PPARA 66/4885RXRA 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.